Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits

Journal of Obstetrics and Gynaecology

Volumn 24, Issue 1, 2004, Pages 47-51

  Castelo Branco, C ^a,c   Sanjuan A ^a   Casals, Elena ^a   Ascaso, C ^a   Colodrón, Marta ^a   Vicente, J J ^a   Mercader, Immaculada ^a   Escaramis G ^a   Blumel J E ^b   Ordi, J ^a   Vanrell, J A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Barros Luco Tradeau Hospital   (Chile)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTRADIOL VALERATE; RALOXIFENE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART WEIGHT; LIVER WEIGHT; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RABBIT; TISSUE LEVEL; UTERUS WEIGHT;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; AREA UNDER CURVE; ARTERIOSCLEROSIS; BIOPSY, NEEDLE; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS, LDL; OVARIECTOMY; PROBABILITY; RABBITS; RALOXIFENE; RANDOM ALLOCATION; REFERENCE VALUES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SENSITIVITY AND SPECIFICITY;

EID: 9144232898     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443610310001620297     Document Type: Article

References (21)

1. Barrett-Connor E., Wenger N.K., Grady D., Mosca L., Collins P., Kornitzer M., Cox D.A., Moscarelli E. and Anderson P. W. (1998) Coronary heart disease in women, randomized clinical trials, HERS and RUTH. Maturitas, 31, 1-7.
2. Bjarnason N.H., Haarbo J., Byrjalsen I., Kauffman R.F. and Christiansen C. (1997) Raloxifene inhibits aortic accumulation of cholesterol in ovariectomised, cholesterol-fed rabbits. Circulation, 96, 1964-1969.
3. Bjarnason N.H., Haarbo J., Byrjalsen I., Kauffman R.F., Knadler M.P. and Christiansen C. (2000) Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomised, cholesterol-fed rabbits. Clinical Endocrinology, 52, 225-233.
4. Castelo-Branco C., Casals E., Sanllehy C., Fortuny A., Vanrell J.A. and González-Merlo J. (1995) Postmenopausal estrogen replacement therapy with low dose medroxyprogesterone acetate. Endometrium, plasma lipids, lipoproteins and apolipoproteins. Journal of Reproductive Medicine, 40, 305-311.
5. Clarkson T.B., Anthony M.S. and Jerome C.P. (1998) Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. Journal of Clinical Endocrinology and Metabolism, 83, 721-726.
6. Cohen F.J., Watts S., Shah A., Akers R. and Plouffe L. Jr (2000) Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstetrics and Gynecology, 95, 104-110.
7. Felton C.V., Crook D., Davies M.J. and Oliver M.F. (1997) Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arteriosclerosis, Thrombosis, and Vascular Biolology, 17, 1337-1345.
8. Figtree G.A., Lu Y., Webb C. and Collins P. (1999) Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation, 100, 1095-1101.
9. Folch J., Lees M. and Stanley G.H.S. (1957) A simple method for the isolation and purification of total lipids from animal tissues. Journal of Biological Chemistry, 226, 497-509.
10. Folsom A.R., Nieto F.J., McGovern P.G., Tsai M.Y., Malinow M.R., Eckfeldt J.H., Hess D.L. and Davis CE. (1998) Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities Study. Circulation, 98, 204-210.
11. Haarbo J., Leth-Espensen P., Stender S. and Christiansen C. (1991) Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomised cholesterol-fed rabbits. Journal of Clinical Investigation, 87, 1274-1277.
12. Lee R.T. and Libby P. (1997) The unstable atheroma. Arteriosclerosis, Thrombosis and Vascular Biology, 17, 1859-1867.
13. Lowry O.H., Rosebrough N.J., Farr A.L. and Randall R.J. (1951) Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
14. Mendelsohn M.E. and Karas R.H. (1999) The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine, 340, 1801-1811.
15. Pines A., Mijatovic V., van der Mooren M.J. and Kenemans P. (1997) Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. European Journal of Obstetrics, Gynaecology and Reproductive Biology, 71, 193-197.
16. Rekhter M.D., Hicks G.W., Brammer D.W., Work C.W., Kim J.S., Gordon D., Keiser J.A. and Ryan M.J. (1998) Animal model that mimics atherosclerotic plaque rupture. Circulation Research, 83, 705-713.
17. Ridker P.M., Buring J.E., Shih J., Matias M. and Hennekens C.H. (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 98, 731-733.
18. Sarrel P.M. (1990) Ovarian hormones and the circulation. Maturitas, 12, 287-298.
19. Stampfer M.J. and Colditz G.A. (1991) Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine, 20, 47-63.
20. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., Shah A.S. and Anderson P.W. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Journal of the American Medical Association, 279, 1445-1451.
21. Walsh B.W., Paul S., Wild R.A., Dean R.A., Tracy R.P., Cox D.A. and Anderson P.W. (2000) The effects of hormone replacement therapy and raloxifene on C-Reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism, 85, 214-218.